Evaluation of Anti-SARS-CoV-2 Polyclonal Hyperimmune Globulin Efficacy and Safety in Early-Stage COVID-19 Adult Outpatients: A Randomized, Double-Blind, Placebo-Controlled Trial

The primary objective of this study is to evaluate the **safety** and **efficacy** of a single infusion of hyperimmune immunoglobulin (hIVIG) compared to placebo, both administered alongside standard of care (SOC), in adult outpatients with recently diagnosed **COVID-19**. The clinical status of participants will be assessed after seven days. This objective is crucial as it aims to determine whether hIVIG can provide a superior therapeutic benefit over placebo in improving clinical outcomes in the early stages of COVID-19. Two hypotheses will be tested: one involving participants who did not receive a direct-acting antiviral (DAA) or other anti-SARS-CoV-2 agents as part of their SOC (stratum 1), and another involving all randomized participants (stratum 1 and stratum 2 combined). Stratum 2 includes participants who received DAAs or other anti-SARS-CoV-2 agents recommended by established treatment guidelines.

Secondary objectives include conducting subgroup analyses and evaluating safety outcomes for all randomized participants, as well as separately for those in stratum 1 and stratum 2. These analyses are intended to provide a comprehensive understanding of the treatment's impact across different patient subgroups and to ensure the safety profile of the intervention.

The clinical trial involves a total of **660 participants** diagnosed with **COVID-19**. The study population includes both male and female subjects, with an age range starting from 18 years, focusing on individuals aged 55 years and older or those with an immunosuppressed condition. Participants were selected based on a positive test for SARS-CoV-2 within five days and symptom onset within the same timeframe if symptomatic. The trial population is characterized by a commitment to not engage in other clinical trials for COVID-19 treatment through Day 7 or until significant disease progression. The study includes a vulnerable population, reflecting the inclusion of individuals with specific health risks. Participants are required to provide written informed consent and adhere to study procedures through Day 28. Lifestyle factors such as diet and physical activity are not specified in the available data.

The clinical trial is designed as an **international multicenter, randomized, double-blind, placebo-controlled** study to evaluate the safety and efficacy of **Anti-COVID-19 Hyperimmune Globulin (Human)** in adult outpatients with early-stage **COVID-19**. The trial aims to compare a single infusion of hyperimmune immunoglobulin (hIVIG) against a placebo, both administered alongside the standard of care (SOC). The primary objective is to assess the clinical status of participants after seven days, with two hypotheses being tested across different study populations. The trial is expected to conclude by December 31, 2025, with recruitment having commenced on December 10, 2021.

Participants will undergo a series of study visits, beginning with an inclusion (screening) visit to confirm eligibility based on criteria such as age, immunosuppressed condition, and a positive SARS-CoV-2 test within five days. Following the initial visit, participants will receive the investigational product or placebo via **intravenous infusion**. Subsequent follow-up visits will occur on Days 4, 7, 14, and 28 to monitor clinical outcomes, including the primary and secondary endpoints. The primary endpoints focus on the severity of COVID-19 symptoms and limitations in usual activity, while secondary endpoints include hospitalization rates, mortality, and changes in viral and antibody levels.

The expected duration of participant involvement is 28 days, during which adherence to study procedures is required. Participants are expected to refrain from enrolling in other clinical trials for COVID-19 treatment until Day 7 or until significant disease progression. Conditions that may lead to early termination from the study include hospitalization or significant disease progression before Day 7, as defined by specific ordinal categories. The trial's design ensures rigorous assessment of the investigational product's efficacy and safety, contributing valuable data to the ongoing management of COVID-19.

The clinical trial involves the administration of **Anti-COVID-19 Hyperimmune Globulin (Human)**, a **solution for infusion**. This experimental medication contains **anti-SARS-CoV-2 polyclonal hyperimmune globulin**, a structurally diverse substance classified as an immunoglobulin. The product is developed by the Regents of the University of Minnesota and is identified by the product code Grifols hIVIG. The medication is administered via **intravenous infusion** with a maximum daily and total dose of 300 ml. The treatment period is limited to a single day. The primary objective of the trial is to evaluate the safety and efficacy of this hyperimmune globulin in adult outpatients with early-stage COVID-19.

In addition to the experimental treatment, the study employs a **placebo** control, which consists of **normal saline**. The saline is volume-matched to the test product and is provided by the study site. The placebo is administered in the same manner as the experimental treatment, ensuring blinding and maintaining the integrity of the trial design. Both the experimental and placebo treatments are given alongside standard-of-care therapy, which may include direct-acting antivirals or other anti-SARS-CoV-2 agents as recommended by established national or international COVID-19 treatment guidelines. Participant compliance with the dosing schedule is monitored throughout the trial to ensure accurate assessment of the treatment's efficacy and safety.

Efficacy in this clinical trial will be assessed through a series of primary and secondary endpoints designed to evaluate the impact of **Anti-COVID-19 Hyperimmune Globulin (Human)** on clinical outcomes in adult outpatients with early-stage COVID-19. The primary endpoints focus on the clinical status of participants after seven days, categorized by the severity of COVID-19 symptoms and limitations in usual activity. These categories range from asymptomatic to critical illness or death.

Secondary endpoints will provide a comprehensive evaluation of the treatment's efficacy over a 28-day period. These include all-cause hospitalization or death, all-cause mortality, and significant disease progression, analyzed through time-to-event analysis. The distribution of outcomes on an ordinal scale will be assessed at multiple timepoints: Day 4, Day 14, and Day 28. Additionally, the trial will measure changes in viral burden and SARS-CoV-2 antibody levels between Day 0 and Day 7, utilizing serum antigen levels and polymerase chain reaction (PCR) from nasal and saliva specimens.

Further assessments will include the utilization of healthcare resources, severity of respiratory symptoms, and hypoxemia through Day 7, with specific attention to oxygen saturation levels. The trial will also explore the proportion of participants starting other COVID-19 treatments and associations between laboratory assessment changes and clinical outcomes. These efficacy parameters will be collected and analyzed using validated clinical scales and laboratory tests at specified intervals throughout the study duration.